| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
Apoptosis inducer 56 (compound 1) (5-60 μM; 24 h) selectively induced cytotoxicity in MCF-7 human breast cancer cells with an IC50 of 21.18 μM, while showing no significant cytotoxicity to non-malignant MCF-10A breast epithelial cells [1]. Apoptosis inducer 56 (21.18 μM; 24 h) inhibited the proliferation and colony formation of MCF-7 human breast cancer cells and induced cell cycle arrest in the S phase [1]. Apoptosis inducer 56 (21.18 μM; 24 h) induced apoptosis in 45% of MCF-7 human breast cancer cells, while having no apoptotic effect on non-malignant MCF-10A breast epithelial cells [1]. Apoptosis inducer 56 (21.18 μM; 24 h) induced DNA damage-mediated apoptosis and caused mitochondrial membrane depolarization in 75.8% of MCF-7 human breast cancer cells [1]. Apoptosis inducer 56 (21.18 μM) can activate the DNA damage response of MCF-7 human breast cancer cells (upregulate γ-H2AX, p-ATM, p-Chk2) and inhibit DNA repair (downregulate p-BRCA1) [1]. Apoptosis inducer 56 (21.18 μM; 24 h) induces mitochondrial-dependent apoptosis in MCF-7 human breast cancer cells by upregulating pro-apoptotic proteins, releasing cytochrome c, activating caspase and cleaving PARP [1].
|
|---|---|
| ln Vivo |
Apoptosis inducer 56 (compound 1) (1-10 mg/kg; orally; daily; 28 days) was safe in BALB/c mice at doses up to 10 mg/kg and showed no significant toxic effects on hematological, biochemical, renal or hepatic parameters [1].
|
| Cell Assay |
Cytotoxicity assay [1]
Cell Types: MCF-7 human breast cancer cells, MCF-10A non-malignant breast epithelial cells Tested Concentrations: 5, 10, 20, 40, 60 μM Incubation Duration: 24 hours Experimental Results: Cytotoxicity was induced in MCF-7 cells with an IC₅₀ of 21.18 ± 2.01 μM; the survival rate of MCF-10A cells remained above 70% at concentrations of 5, 10, 20, 40, and 60 μM. |
| Animal Protocol |
Animal/Disease Models:BALB/c mice (adult females, 25–28 g) [1]
Doses: 1, 2.5, 5, 10 mg/kg Route of Administration: Oral; daily; 28 days Experimental Results: No significant adverse effects on liver, kidney, biochemical or hematological parameters were detected; no treatment-related behavioral abnormalities were observed; all dose groups maintained stable body weight; histopathological analysis showed no structural abnormalities in liver and kidney tissues. |
| References |
| Molecular Formula |
C11H17N3O3S
|
|---|---|
| Molecular Weight |
271.34
|
| CAS # |
952306-31-9
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
O=C(CCCCCCC(NO)=O)NC1=NC=CS1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6854 mL | 18.4271 mL | 36.8541 mL | |
| 5 mM | 0.7371 mL | 3.6854 mL | 7.3708 mL | |
| 10 mM | 0.3685 mL | 1.8427 mL | 3.6854 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
